Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443601 | 1.00 | HCRTR1 (0.52) | HCRTR1HCRTR2CAPN1P2RX7L3MBTL1 | |
| SCHEMBL30829326 | 0.91 | HCRTR1 (0.47) | HCRTR1HCRTR2CAPN1P2RX7CYP3A4 | |
| SCHEMBL7275111 | 0.91 | HCRTR1 (0.47) | HCRTR1HCRTR2CAPN1P2RX7CYP3A4 | |
| SCHEMBL7275104 | 0.91 | HCRTR1 (0.47) | HCRTR1HCRTR2CAPN1P2RX7CYP3A4 | |
| SCHEMBL14319043 | 0.85 | MEN1 (0.42) | HCRTR1HCRTR2GRIN2BALDH1A1 | |
| SCHEMBL14285586 | 0.85 | MEN1 (0.42) | HCRTR1HCRTR2GRIN2BALDH1A1 | |
| SCHEMBL27278853 | 0.82 | EHMT2 (0.49) | ALDH1A1CYP3A4TSHRCYP2C19EHMT2 | |
| SCHEMBL11065983 | 0.82 | EHMT2 (0.49) | ALDH1A1CYP3A4TSHRCYP2C19EHMT2 | |
| SCHEMBL20193827 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2CAPN1P2RX7CYP3A4 | |
| SCHEMBL25235970 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2CAPN1P2RX7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| EP-3941468-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-01-26 | — | — | EP | disclosed |
| CN-113784953-A | Heterocyclyl (phenyl) carbinol compounds useful for treating hyperglycemia | 阿托基公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | HCRTR1 1200/4885HCRTR2 1760/4885CAPN1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.